Before we start: this article is not about whether retatrutide works, and it is not a recommendation for or against any drug. It is about a question that comes before that one. Who decides who is allowed to stand at the front of a line that does not officially exist yet?
What happened
On 3 August 2026, Eli Lilly confirmed that a defined group of patients can apply for early access to retatrutide, an obesity drug that has not been approved by the US Food and Drug Administration. A company spokesperson told Reuters that for “a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial,” Lilly considers it “medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA’s guidance.” The company said it had built an expanded access programme and was “actively reviewing requests from health care providers.”
The announcement did not arrive on its own. It arrived after four months of pressure, and the pressure started with one patient.
In April, Lilly granted a single 79-year-old patient compassionate-use access to retatrutide, months before any broader framework existed. STAT News first reported the case in June. According to that reporting, the application was filed by a senior clinician at the National Institutes of Health and cited refractory obesity, obstructive sleep apnoea and pulmonary hypertension.
Then it turned political. STAT asked the White House whether the recipient was President Donald Trump, who turned 80 in June. A spokesperson said the application was not for the president. Democratic lawmakers have since pressed the administration for more detail about who the recipient was. As of the reporting we could verify, the identity has not been disclosed.
Meanwhile, doctors who had asked the same company for the same thing on behalf of their own patients described weeks of silence. Spencer Nadolsky and Mike Albert, both of the online obesity clinic Vineyard, told STAT they had applied for several patients who had not responded adequately to Lilly’s approved drug Zepbound. Nadolsky said one of his patients received only a preliminary qualification, and only after STAT contacted Lilly for comment. Angela Fitch, chief medical officer of the obesity clinic knownwell, said clinicians “are owed an explanation of some sort” about whether a formal programme existed at all.
So the sequence reads: one person gets in, a news organisation asks about it, lawmakers ask about it, and then a programme appears.
The criteria, and the fact that they come in two versions
Here is what a patient now has to satisfy. Be 18 or older. Have refractory obesity. Have two or more serious or life-threatening obesity-related complications for which they are currently receiving standard care. Be unable to enrol in a trial of retatrutide or a comparable investigational medicine. Have discussed all standard treatment options, including bariatric surgery.
That is already a narrow door. But there is a detail worth sitting with, because it is the kind of thing that decides individual cases and almost never makes headlines: the criteria exist in two slightly different published versions.
A source familiar with the programme told STAT that patients must be 18 or older, unable to join a trial, have refractory obesity with two or more serious complications, and have discussed all standard options. Reuters, quoting a company spokesperson, reported something stricter: refractory obesity despite tolerating the highest approved dose of an obesity therapy. The American Journal of Managed Care, which laid the two accounts side by side on 5 August, put it plainly: depending on the account, the requirement is either maximum-dose treatment failure or documented discussion of standard options. The discrepancy had not been reconciled at the time of publication.
Two versions of a rule is not a footnote. It is the difference between a patient who qualifies and a patient who does not, and neither the patient nor their doctor gets to see the version that will be applied to them. Fitch said she had not submitted an application yet and was still trying to find out from Lilly whether patients would even need to travel to a clinical trial site to receive treatment.
Not every specialist wants in. Fatima Cody Stanford of Harvard Medical School and Gitanjali Srivastava of Vanderbilt University Medical Center told STAT they are not pursuing compassionate use for their patients and want more safety data before offering the drug outside a monitored trial. Stanford, herself a clinical investigator on Lilly’s retatrutide trials, said she does not believe the company intended to extend access beyond the original patient, and now has to manage a programme it may not have planned to build.
Who actually holds the key
The instinct is to blame the regulator. That instinct is wrong here, and the correction matters, because it points at where the power actually sits.
The FDA’s own guidance for physicians describes expanded access as a pathway with three roles. The patient consults a physician. The physician agrees to oversee treatment, files the paperwork with the FDA and an institutional review board, and takes responsibility for care and reporting. And the company has to be “willing to provide the investigational medical product.” The FDA states that it authorises the vast majority of expanded access requests it receives. What it cannot do is order a manufacturer to hand over a drug it does not want to hand over.
So the bottleneck is not a government office. It is a corporate decision, and there is no external standard the decision has to meet, no published queue, and no appeal.
That is the part worth carrying out of this story. For a drug that has not been approved, there is no right of access anywhere in this system. There is only a company’s willingness, and willingness is distributed by whoever happens to have reach: a senior clinician at a federal research institution, a reporter with a phone number, a member of Congress with a letterhead.
Would Germany handle this differently? Partly
German law has a version of the same pathway, and it is stricter in ways that are easy to miss.
Under § 21 (2) no. 3 of the Arzneimittelgesetz, a medicine needs no marketing authorisation if it is supplied free of charge, under the conditions of Article 83 of Regulation (EC) 726/2004, to patients with a seriously debilitating or life-threatening illness who cannot be satisfactorily treated with an authorised medicine. (Older guidance documents, including the page the federal regulator BfArM still publishes, cite this as no. 6, from the earlier numbering. The current statute reads no. 3.)
The procedure sits in a separate ordinance, the Arzneimittel-Härtefall-Verordnung, in force since 22 July 2010. Under § 3, whoever initiates, organises and finances such a programme has to notify the competent federal authority and file a defined set of documents. Under § 4, the authority confirms receipt within two weeks, the programme may only begin once that confirmation has arrived and the authority has not objected, and the authority may object if the conditions are not met.
Compare that with what happened in the US case. In Germany, a group programme cannot quietly exist or quietly not exist. It has to be declared to a public authority, it cannot be sold, and a public body can stop it.
But here is the limit, and it is stated on BfArM’s own page: the ordinance applies only to programmes intended for groups of patients. Treatment of an individual single case is explicitly not covered by the ordinance or its notification procedure.
Which means the exact thing that started this story, one named-nowhere person receiving an unapproved drug ahead of everyone else, would fall outside the visible procedure in Germany too. The German system makes programmes accountable. It does not make individual favours visible. And in both countries, the company still decides whether to run a programme at all.
Why this belongs in a magazine about fat people
Because it is the same shape as everything else we have documented this year, and the shape is starting to be the story.
In France, weight-loss drugs are reimbursed; in Germany the law files them under lifestyle. In the US, access to GLP-1 drugs already splits along income lines, and the split punishes twice. Germany’s own reimbursement debate, as we described when the G-BA leadership questioned the exclusion, offers coverage at the price of being classified as ill. And in law, body weight is not a protected characteristic in the US, the UK or Germany; protection runs through disability law, which means through a diagnosis.
Every one of those is the same trade. Access is available, but only in exchange for a category: sick enough, poor enough, diagnosed enough, connected enough. What the retatrutide case adds is the crudest version: access in exchange for proximity to power.
There is a second reason. When the evidence about these drugs arrives, it mostly arrives from the people selling them. Three Cochrane reviews of tirzepatide, semaglutide and liraglutide, reported by Deutsches Ärzteblatt on 7 November 2025, found clinically meaningful weight reduction for as long as treatment continues, and all three research teams pointed out emphatically that most of the underlying randomised trials were manufacturer-funded. We wrote about who pays for the studies that shape this debate earlier this month. It applies here too.
For the record, the numbers Lilly is building its approval case on come from the company’s own announcement of 23 July 2026: in TRIUMPH-2, adults with type 2 diabetes and obesity or overweight lost up to an average of 20.8 per cent of body weight at 80 weeks on the highest dose; in TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to an average of 22.6 per cent. Lilly plans to file for approval with the FDA in the first quarter of 2027. We report those figures as what they are: topline results announced by the manufacturer, not an independent verdict, and not a reason for anyone to want or not want a drug.
The thing to take away
A 79-year-old man got a medicine that officially does not exist yet. We do not know who he is. His doctors at a federal research institute knew how to ask. Other doctors asked and waited weeks. Then journalists asked, and lawmakers asked, and a programme appeared with rules that come in two versions.
Nothing about that is an argument about bodies. It is an argument about queues, and about who is allowed to write the rules for standing in them. For fat people, who spend a great deal of time being told that their health outcomes are a matter of personal effort, it is worth naming out loud how much of the actual access in this system is decided by proximity, paperwork and press attention.
Sources
- Sneha S K, Deena Beasley: Eli Lilly to offer early access to next-gen obesity drug to some patients. Reuters, 3 August 2026. https://www.reuters.com/legal/litigation/eli-lilly-offer-early-access-next-gen-obesity-drug-some-patients-2026-08-03/
- Lizzy Lawrence, Elaine Chen: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug. STAT, 3 August 2026 (STAT Plus, full text behind paywall; details used here are as reproduced by AJMC and Reuters). https://www.statnews.com/2026/08/03/eli-lilly-retatrutide-mystery-patient-doctors-seek-same-access-their-patients/
- Giuliana Grossi: Lilly Expands Retatrutide Access Amid Doctor Pushback. The American Journal of Managed Care, 5 August 2026. https://www.ajmc.com/view/lilly-expands-retatrutide-access-amid-doctor-pushback
- Eli Lilly and Company: Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. News release, 23 July 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
- US Food and Drug Administration: Expanded Access, Information for Physicians. https://www.fda.gov/news-events/expanded-access/expanded-access-information-physicians
- § 21 Abs. 2 Nr. 3 Arzneimittelgesetz. https://www.gesetze-im-internet.de/amg_1976/__21.html
- §§ 1, 3, 4 Arzneimittel-Härtefall-Verordnung. https://www.gesetze-im-internet.de/amhv/
- BfArM: Arzneimittel-Härtefallprogramme / Compassionate Use. https://www.bfarm.de/DE/Arzneimittel/Klinische-Pruefung/Compassionate-Use/_artikel.html
- Fast alle Studien zu Abnehmspritzen von Herstellern finanziert. Deutsches Ärzteblatt, 7 November 2025 (Cochrane Database of Systematic Reviews 2025, DOI 10.1002/14651858.CD016018, 10.1002/14651858.CD015092.pub2, 10.1002/14651858.CD016017). https://www.aerzteblatt.de/news/fast-alle-studien-zu-abnehmspritzen-von-herstellern-finanziert-a4c0435a-b30e-4d18-92f3-4ccdf5087d1c
Note on sourcing: The STAT article is behind a paywall. Every detail attributed to STAT in this piece is taken from AJMC’s fact-checked summary of it or from Reuters, both of which cite STAT explicitly. No quotation is reproduced here that we could not find in an accessible source. The identity of the April patient is not known and is not speculated about here beyond the White House denial that has been reported.